Zealand Pharma A/S Stock
Equities
ZEAL
DK0060257814
Biotechnology & Medical Research
OTC Markets Traded|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 326.30 DKK | +9.02% |
|
+0.43% | -30.04% |
| 02:31pm | Boehringer-Zealand's obesity drug shows promise in cutting visceral, liver fat | RE |
| 06-05 | Zealand touts promising tolerability data for obesity drug in mid-stage study | RE |
| Capitalization | 22.92B 3.54B 3.07B 2.81B 2.65B 4.93B 337B 5.01B 33.44B 13.01B 163B 13.29B 13B 567B | P/E ratio 2026 * |
14.2x | P/E ratio 2027 * | 34.8x |
|---|---|---|---|---|---|
| Enterprise value | 12.45B 1.92B 1.67B 1.53B 1.44B 2.68B 183B 2.72B 18.17B 7.07B 88.66B 7.22B 7.07B 308B | EV / Sales 2026 * |
2.7x | EV / Sales 2027 * | 2.47x |
| Free-Float |
98.26% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Zealand Pharma A/S
| 1 day | +9.02% | ||
| 1 week | +0.43% | ||
| Current month | +0.43% | ||
| 1 month | +3.52% | ||
| 3 months | +38.91% | ||
| 6 months | -35.77% | ||
| Current year | -30.04% |
| 1 week | 299.3 |  | 337 |
| 1 month | 296.5 | | 360.2 |
| Current year | 233.5 | | 478.5 |
| 1 year | 233.5 | | 556 |
| 3 years | 212.2 | | 972 |
| 5 years | 69.55 | | 972 |
| 10 years | 69.55 | | 972 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 52 | 2022-03-29 | |
| Director of Finance/CFO | - | 2022-10-31 | |
Utpal Singh
CTO | Chief Tech/Sci/R&D Officer | - | 2025-04-22 |
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | 71 | - | |
Kirsten Drejer
BRD | Director/Board Member | 69 | 2018-04-18 |
Leonard Kruimer
BRD | Director/Board Member | 68 | 2019-04-03 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 25-05-26 | Sell | Chief Executive Officer | 45,000 | 0.0634% | ||
| 25-05-26 | Fiscal year | Chief Executive Officer | 106,680 | 0.1502% | ||
| 25-05-26 | Tax | Chief Executive Officer | 33,232 | 0.0468% |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +9.02% | +0.43% | -31.51% | +27.36% | 3.54B | |
| +5.10% | +7.04% | +48.39% | +103.29% | 55.01B | |
| -0.20% | -4.96% | +50.88% | +49.82% | 43.37B | |
| -1.69% | -8.20% | -18.81% | -19.82% | 22.27B | |
| -10.20% | -11.87% | +27.98% | +384.17% | 20.42B | |
| +0.99% | -1.80% | +32.82% | -24.48% | 17.27B | |
| +3.90% | -7.07% | +9.55% | -42.27% | 15.02B | |
| +0.40% | +4.40% | +22.47% | +169.98% | 13.25B | |
| +0.82% | -14.85% | +16.25% | - | 11.71B | |
| -0.47% | -15.79% | -28.27% | +645.96% | 11.46B | |
| Average | +0.77% | -5.05% | +12.98% | +143.78% | 21.33B | |
| Weighted average by Cap. | +0.67% | -2.88% | +27.11% | +118.76% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 4.62B 714M 618M 567M 534M 994M 68.01B 1.01B 6.74B 2.62B 32.89B 2.68B 2.62B 114B | 4.41B 681M 590M 541M 509M 948M 64.89B 963M 6.43B 2.5B 31.38B 2.56B 2.5B 109B |
| Net income | 1.64B 254M 220M 202M 190M 353M 24.17B 359M 2.4B 933M 11.69B 953M 932M 40.66B | 534M 82.57M 71.5M 65.61M 61.73M 115M 7.87B 117M 780M 303M 3.81B 310M 303M 13.23B |
| Net Debt | -10.47B -1.62B -1.4B -1.28B -1.21B -2.25B -154B -2.29B -15.27B -5.94B -74.5B -6.07B -5.94B -259B | -12.01B -1.86B -1.61B -1.47B -1.39B -2.58B -177B -2.62B -17.52B -6.82B -85.49B -6.97B -6.81B -297B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-06-04 | 326.30 kr | +9.02% | 1,005,519 |
| 26-06-03 | 299.30 kr | -1.77% | 350,527 |
| 26-06-02 | 304.70 kr | -2.84% | 377,987 |
| 26-06-01 | 313.60 kr | -3.48% | 468,870 |
| 26-05-29 | 324.90 kr | +0.37% | 449,944 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- ZEAL Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition